Dr Pilar Bilbao – CUV151 mechanistic study update (Part 1)

On 14 February 2022, CLINUVEL announced the start of the second study in its DNA Repair Program, evaluating afamelanotide as skin DNA repair therapy. This mechanistic study (CUV151) will evaluate afamelanotide in disease-free adults. In this first of two videos after the announcement, CLINUVEL’s Head of Clinical Operations, Dr Pilar Bilbao, discusses CLINUVEL’s focus on unmet clinical need and how this led to the DNA Repair Program and treating xeroderma pigmentosum (XP) patients.

Read the announcement

Read DNA Repair Communiqué I


  1. Thank you Dr Bilbao and thank you CUV. Regular updates on progress with the Company’s various initiatives makes a huge difference when compared to prolonged periods of silence that have all too often prevailed in days past. As a long time shareholder I believe we have good reason to be excited about the future and I can tell you that it feels much, much better to be an informed supporter of the company whilst on the journey.
    Thanks again Dr Bilbao – and keep up the good work!

  2. Espectacular! es como descubrir un mundo desconocido, como inversor de Clinuvel te doy las gracias Pilar,
    lo estas haciendo muy bien.

  3. I’ve been absent for a while, but now I remember why I used to love this website. Thanks, I?¦ll try and check back more often. How frequently you update your website?

  4. Hi there! This is my first visit to your blog! We are a team of volunteers and starting a new project in a community in the same niche. Your blog provided us beneficial information to work on. You have done a wonderful job!

  5. I appreciate, cause I found exactly what I was looking for. You have ended my four day long hunt! God Bless you man. Have a nice day. Bye

Comments are closed.

Related Articles

Get in Touch


Latest Posts